Oncology

Mantle Cell Lymphoma

Expert Roundtables Podcast: Frontiers in Mantle Cell Lymphoma: Integrating Immunotherapy and Responding to Resistance

expert roundtables by Preetesh Jain, MBBS, MD, DM, PhD; Bijal Shah, MD, MS; Michael Wang, MD

Overview

Emerging treatment strategies in mantle cell lymphoma focus on resistance mechanisms and novel therapeutic combinations. In today’s podcast, our expert panelists discuss integrating immunotherapy and responding to resistance.

References

Jiang V, Lee W, Zhang T, et al. The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma. Biomark Res. 2024;12(1):62. doi:10.1186/s40364-024-00589-7

Lokhande L, Nilsson D, de Matos Rodrigues J, et al. Quantification and profiling of early and late differentiation stage T cells in mantle cell lymphoma reveals immunotherapeutic targets in subsets of patients. Cancers (Basel). 2024;16(13):2289. doi:10.3390/cancers16132289

Wang M, Siddiqi T, Gordon LI, et al. Lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study. J Clin Oncol. 2024;42(10):1146-1157. doi:10.1200/JCO.23.02214

Profile

Preetesh Jain, MBBS, MD, DM, PhD

Assistant Professor

Division of Cancer Medicine

Department of Lymphoma and Myeloma

The University of Texas MD Anderson Cancer Center

Houston, TX

Profile

Bijal Shah, MD, MS

Senior Member and Clinical Research Medical Director
Department of Malignant Hematology
Clinical Leader, Mantle Cell Lymphoma and Acute Lymphocytic Leukemia
Moffitt Cancer Center
Tampa, FL